Amyotrophic Lateral Sclerosis Market By Disease Type (Sporadic ALS & Familial ALS), By Drug Type (Radicava, Nuedexta & Riluzole), By Treatment Type(Medicines & Therapies (Chemotherapy & Stem cell transplant)), By Treatment Channel (Hospitals, Diagnostic facilities, Other medical facilities), By Geography - Global Opportunity Analysis & Industry Forecast, 2022-2027

Report Code: HCR 0115 Report Format: PDF + Excel

Amyotrophic Lateral Sclerosis Market Overview

Amyotrophic Lateral Sclerosis Market size is estimated to reach $754.3 million by 2027, growing at a CAGR of 5.3% during the forecast period 2022-2027. Amyotrophic lateral sclerosis is also called Lou Gehrig’s disease and it falls under the category of nervous system illness. This neurodegenerative disease leads to impaired neurological functions and severe weakness as they start spreading by depreciating motor neuron diseases which are the prominent part of the central nervous system and transmit impulses to regulate and set muscle activities in motion. Some common symptoms associated with the ailment are shortness of breath (SOB), dementia, difficulty in speaking, trouble swallowing, and impaired cognitive behavior. According to a report published by mayo Clinic, around 6-10% of the complications are genetically passed down to the younger generation through their ancestor but in maximum cases the root cause of the problem is unknown. However, these unknown causes are mostly triggered by smoking, exposure to harmful radiation and chemicals, and other pollutants present in the environment. Therefore, besides genetics, the elevating smoking trends among teenagers, brain injuries, and exposure to highly intense radiation are factors set to drive the growth of the Amyotrophic Lateral Sclerosis Market for the period 2022-2027.

Report Coverage

The report: “Amyotrophic Lateral Sclerosis Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Amyotrophic Lateral Sclerosis Market.

By Disease Type: Sporadic ALS and Familial ALS.
By Drug Type: Radicava, Nuedexta and Riluzole.
By Treatment Type: Medicines and Therapies (Chemotherapy and Stem cell transplant).
By Treatment Channel: Hospitals, Diagnostic facilities, Other medical facilities.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest of World (the Middle East and Africa).

Key Takeaways

  • Geographically, the North America Amyotrophic Lateral Sclerosis Market accounted for the highest revenue share in 2021. However, Asia-pacific is poised to dominate the market over the period 2022-2027.
  • Enlargement in research activities to develop a more effective and reliable way of treatment is said to be a preeminent driver driving the growth of the Amyotrophic Lateral Sclerosis Market. The exorbitant nature of curative treatments and lower chances of survival is said to reduce the market growth.
  • Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Amyotrophic Lateral Sclerosis Market report.

Amyotrophic Lateral Sclerosis Market Share, By Geography (%) in 2021

Amyotrophic Lateral Sclerosis Market

For more details on this report - Request for Sample

Amyotrophic Lateral Sclerosis Market Segment Analysis-By Treatment Type

The Amyotrophic Lateral Sclerosis Market based on the treatment type can be further segmented into medicines, and therapies (chemotherapy and stem cell transplant). The medicines segment held the largest share in 2021. The growth is owing to the widescale use of drugs in the treatment of amyotrophic lateral sclerosis. Drugs like Radicava and Riluzole are the first line of treatment in curative procedures associated with motor neuron disorder. In ALS free radicals increase oxidative stress and eventually worsen the situation by terminating motor neurons. Radicava includes an active pharmaceutical ingredient commonly known as “Edaravone” which helps in scavenging these harmful free radicals and eradicating them. Moreover, medicine is estimated to be the fastest-growing segment with a CAGR of 6.8% over the forecast period 2022-2027. This growth is owing to research activities in quest of finding a more stable and effective drug that increases the chances of patient survival. Therapies are used very rarely in treatment procedures because the disease can’t be cured. Moreover, chemotherapy increases the risk of patient survival. Therefore, It can merely be controlled through that too with medication.

Amyotrophic Lateral Sclerosis Market Segment Analysis-By Treatment Channel

The Amyotrophic Lateral Sclerosis Market based on treatment channel can be further segmented into hospitals, diagnostic facilities, other medical facilities. The hospital segment held the largest share in 2021. The growth is owing to the far-reaching prevalence of hospitals in both urban and rural areas. Besides, the cost of drugs used in the treatment of ALS is too expensive. Therefore, except for hospitals, it is next to impossible for medical facilities like cancer treatment centers, ambulatory surgery centers to afford the cost of the entire setup and maintain a 24/7 supply chain of these drugs. On another hand, the presence of a highly skilled and experienced medical professional is another factor behind progress in the hospital segment. The hospital segment is estimated to be the fastest-growing segment with a CAGR of 7.0% over the forecast period 2022-2027. This growth is owing to the refining infrastructure of hospitals as governments are allocating innumerable flows of hard cash.

Amyotrophic Lateral Sclerosis Market Segment Analysis-By Geography

The Amyotrophic Lateral Sclerosis Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 37% of the overall market in 2021. The growth in this segment is owing to the factors such as world-class healthcare facilities in countries like the U.S. Moreover, the U.S is also known as the melting pot of cultures because this country gravitates a lot of people including top-of-the-line medical professionals due to innumerable growth opportunities and high salaries which is another prominent factor that U.S. healthcare is considered the best in the world. However, The Asia-Pacific is expected to be the fastest-growing segment over the forecast period 2022-2027. This growth is owing to heavy investments in the research field as Asian nations are prospering economically. Moreover, the Asian population smokes a lot, and besides smoking the worst air quality which people are breathing in on regular basis is another factor considered to enlarge the progress in the amyotrophic lateral sclerosis market as the prevalence of such motor neuron disorders is directly proportional to smoking.

Amyotrophic Lateral Sclerosis Market Drivers

Rising injuries, smoking trends, and radiation exposure is Anticipated to Boost Product Demand.

Road accidents are the biggest reason behind traumatic brain injuries all over the world. Especially, if we talk about low-income countries like India, Pakistan or other African nations the prevalence of road accidents is more than usual. According to a report, annually around 450,000 accidents occur in India. Around 140,000-150,000 lose their lives and the rest develop serious health complications over the years due to severe injuries. Besides, growing smoking trends and nuclear plant setups are adding insult to injury because they are a major contributor to the prevalence of sporadic ALS.

Escalating spending on research and developmental activities is Expected to Boost Product Demand.

Till now there are a few numbers of drugs approved by health agencies for curing amyotrophic lateral sclerosis such as Radicava, Nuedexta, Riluzole. Moreover, only Riluzole is taken into consideration the maximum times as it is slightly better than the rest. Therefore, governments research agencies and private players are allocating more and more funds so they can achieve a breakthrough in their quest of developing a more effective and cheaper alternative for Riluzole. For instance, Sanofi a famous biopharmaceutical company and a big player in the amyotrophic lateral sclerosis market spend more than 5 billion on R&D in 2021. The number has witnessed a big hike as compared to spendings in past.

Amyotrophic Lateral Sclerosis Market Challenges

Extortionate cost of drugs and little to no survival rates are Anticipated to Hamper Market Growth.

Lou Gehrig’s disease is so rare that its treatment can cost someone a fortune. Edaravone is a mainstream drug or active ingredient in the treatment of ALS as it helps in the elimination of free radicals causing neuron damage. This drug can approximately $145,000 annually. Now including other costs like hospital bills, the entire treatment may cost around $200,000. On top of that, there is no guarantee that undergoing such treatments will improve a patient’s condition. Therefore, very low survival rates even after spending thousands of dollars can be a big setback in the growth of the respective market.

Amyotrophic Lateral Sclerosis Industry Outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Amyotrophic Lateral Sclerosis Market. Key companies of this market are-

  1. Mylan N.V.
  2. Sanofi S.A.
  3. Biogen Inc.
  4. Apotex Inc.
  5. Mitsubishi Tanabe Pharma America
  6. Sun Pharmaceutical
  7. Ascend Pharmaceuticals
  8. Covis Group
  9. Ionis Pharmaceutical
  10. ITF Pharma 

Recent Developments

  • On September 15, 2021, Paris, France-based healthcare company “Sanofi” clinched worth $3.2 billion acquisition of US-based clinical-stage company “Translate Bio” which deals in mRNA therapeutics. In this transaction, the existing shareholders of Translate Bio will receive $38 per share. Moreover, it will confer Sanofi the liberty to develop therapeutics with the help of acquired mRNA technology.
  • On September 8, 2021, Sanofi put itself in the spotlight when the company announced the successful acquisition of US-based biopharmaceutical company “kadman Corporation.” The total value of the transaction stands around $1.9 billion with $9.50 per share. The acquisition is supposed the reinforce the transplant business of Sanofi as post-acquisition it got access to Rezurock (a treatment for cGVHD illness).
  • On November 16, 2020, Switzerland-based company “Covis” announced the successful acquisition of Massachusetts, United States-based pharmaceutical firm “AMAG Pharmaceuticals” at a price of $650 million. The acquisition of AMAG extends Covis a strategic advantage in order to emerge as a specialty company in the development of life-threatening therapeutic.

Relevant Links:

Report Code: HCR 89306

Report Code: HCR 0089

Report Code: HCR 0303

For more Lifesciences and Healthcare related reports, please click here

1. Amyotrophic Lateral Sclerosis Market Overview
    1.1 Definitions and Scope
2. Amyotrophic Lateral Sclerosis Market - Executive Summary
3. Amyotrophic Lateral Sclerosis Market– Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis-Global
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Amyotrophic Lateral Sclerosis Market– Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Amyotrophic Lateral Sclerosis Market– Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index-Global
    5.3 Case Studies of Successful Ventures
6. Amyotrophic Lateral Sclerosis Market- Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Amyotrophic Lateral Sclerosis Market– By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Amyotrophic Lateral Sclerosis Market - By Disease Type (Market Size –$Million/$Billion) 
    8.1 Sporadic ALS
    8.2 Familial ALS
9. Amyotrophic Lateral Sclerosis Market - By Drug Type (Market Size –$Million/$Billion) 
    9.1 Radicava
    9.2 Nuedexta
    9.3 Riluzole
10. Amyotrophic Lateral Sclerosis Market – By Treatment Type (Market Size –$Million/$Billion) 
    10.1 Medicines
    10.2 Therapies (Chemotherapy and Stem cell transplant).
11. Amyotrophic Lateral Sclerosis Market – By Treatment Channel (Market Size –$Million/$Billion) 
    11.1 Hospitals
    11.2 Diagnostic facilities
    11.3 Other medical facilities
12. Amyotrophic Lateral Sclerosis Market- By Geography (Market Size -$Million/Billion)
    12.1 North America
        12.1.1 U.S
        12.1.2 Canada
        12.1.3 Mexico 
    12.2 Europe
        12.2.1 Germany
        12.2.2 France
        12.2.3 UK
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Russia
        12.2.7 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 Japan
        12.3.3 South Korea
        12.3.4 India
        12.3.5 Australia & New Zealand
        12.3.6 Rest of Asia-Pacific 
    12.4 South America
        12.4.1 Brazil
        12.4.2 Argentina
        12.4.3 Chile
        12.4.4 Colombia
        12.4.5 Rest of South America
    12.5 Rest of World
        12.5.1 Middle East
        12.5.2 Africa
13. Amyotrophic Lateral Sclerosis Market- Market Entropy
    13.1 New product launches
    13.2 M&A's, collaborations, JVs and partnerships
14. Amyotrophic Lateral Sclerosis Market– Industry Competition Landscape (Premium)
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key Companies
        14.1.3 Market Share by Countries – Key Companies
    14.2 Competition Matrix
    14.3 Best Practices for Companies
15. Amyotrophic Lateral Sclerosis Market– Key Company List by Country Premium (Premium)
16. Amyotrophic Lateral Sclerosis Market- Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies"
List of Tables

Table1 Amyotrophic Lateral Sclerosis Market Overview 2021-2026
Table2 Amyotrophic Lateral Sclerosis Market Leader Analysis 2018-2019 (US$)
Table3 Amyotrophic Lateral Sclerosis MarketProduct Analysis 2018-2019 (US$)
Table4 Amyotrophic Lateral Sclerosis MarketEnd User Analysis 2018-2019 (US$)
Table5 Amyotrophic Lateral Sclerosis MarketPatent Analysis 2013-2018* (US$)
Table6 Amyotrophic Lateral Sclerosis MarketFinancial Analysis 2018-2019 (US$)
Table7 Amyotrophic Lateral Sclerosis Market Driver Analysis 2018-2019 (US$)
Table8 Amyotrophic Lateral Sclerosis MarketChallenges Analysis 2018-2019 (US$)
Table9 Amyotrophic Lateral Sclerosis MarketConstraint Analysis 2018-2019 (US$)
Table10 Amyotrophic Lateral Sclerosis Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table11 Amyotrophic Lateral Sclerosis Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table12 Amyotrophic Lateral Sclerosis Market Threat of Substitutes Analysis 2018-2019 (US$)
Table13 Amyotrophic Lateral Sclerosis Market Threat of New Entrants Analysis 2018-2019 (US$)
Table14 Amyotrophic Lateral Sclerosis Market Degree of Competition Analysis 2018-2019 (US$)
Table15 Amyotrophic Lateral Sclerosis MarketValue Chain Analysis 2018-2019 (US$)
Table16 Amyotrophic Lateral Sclerosis MarketPricing Analysis 2021-2026 (US$)
Table17 Amyotrophic Lateral Sclerosis MarketOpportunities Analysis 2021-2026 (US$)
Table18 Amyotrophic Lateral Sclerosis MarketProduct Life Cycle Analysis 2021-2026 (US$)
Table19 Amyotrophic Lateral Sclerosis MarketSupplier Analysis 2018-2019 (US$)
Table20 Amyotrophic Lateral Sclerosis MarketDistributor Analysis 2018-2019 (US$)
Table21 Amyotrophic Lateral Sclerosis Market Trend Analysis 2018-2019 (US$)
Table22 Amyotrophic Lateral Sclerosis Market Size 2018 (US$)
Table23 Amyotrophic Lateral Sclerosis Market Forecast Analysis 2021-2026 (US$)
Table24 Amyotrophic Lateral Sclerosis Market Sales Forecast Analysis 2021-2026 (Units)
Table25 Top Companies 2018 (US$)Amyotrophic Lateral Sclerosis Market, Revenue & Volume,,
Table26 Product Launch 2018-2019Amyotrophic Lateral Sclerosis Market, Revenue & Volume,,
Table27 Mergers & Acquistions 2018-2019Amyotrophic Lateral Sclerosis Market, Revenue & Volume,,


List of Figures

Figure 1 Overview of Amyotrophic Lateral Sclerosis Market 2021-2026
Figure 2 Market Share Analysis for Amyotrophic Lateral Sclerosis Market 2018 (US$)
Figure 3 Product Comparison in Amyotrophic Lateral Sclerosis Market 2018-2019 (US$)
Figure 4 End User Profile for Amyotrophic Lateral Sclerosis Market 2018-2019 (US$)
Figure 5 Patent Application and Grant in Amyotrophic Lateral Sclerosis Market 2013-2018* (US$)
Figure 6 Top 5 Companies Financial Analysis in Amyotrophic Lateral Sclerosis Market 2018-2019 (US$)
Figure 7 Market Entry Strategy in Amyotrophic Lateral Sclerosis Market 2018-2019
Figure 8 Ecosystem Analysis in Amyotrophic Lateral Sclerosis Market2018
Figure 9 Average Selling Price in Amyotrophic Lateral Sclerosis Market 2021-2026
Figure 10 Top Opportunites in Amyotrophic Lateral Sclerosis Market 2018-2019
Figure 11 Market Life Cycle Analysis in Amyotrophic Lateral Sclerosis Market
Figure 12 Global Amyotrophic Lateral Sclerosis Market - By Geography
Figure 13 Global Amyotrophic Lateral Sclerosis Market Value & Volume, By Geography, 2021-2026 ($) 
Figure 14 Global Amyotrophic Lateral Sclerosis Market CAGR, By Geography, 2021-2026 (%)
Figure 15 North America Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 16 US Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 17 US GDP and Population, 2018-2019 ($)
Figure 18 US GDP – Composition of 2018, By Sector of Origin
Figure 19 US Export and Import Value & Volume, 2018-2019 ($)
Figure 20 Canada Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 21 Canada GDP and Population, 2018-2019 ($)
Figure 22 Canada GDP – Composition of 2018, By Sector of Origin
Figure 23 Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 24 Mexico Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 25 Mexico GDP and Population, 2018-2019 ($)
Figure 26 Mexico GDP – Composition of 2018, By Sector of Origin
Figure 27 Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 28 South America Amyotrophic Lateral Sclerosis MarketSouth America 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 29 Brazil Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 30 Brazil GDP and Population, 2018-2019 ($)
Figure 31 Brazil GDP – Composition of 2018, By Sector of Origin
Figure 32 Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 33 Venezuela Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 34 Venezuela GDP and Population, 2018-2019 ($)
Figure 35 Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 36 Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 37 Argentina Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 38 Argentina GDP and Population, 2018-2019 ($)
Figure 39 Argentina GDP – Composition of 2018, By Sector of Origin
Figure 40 Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 41 Ecuador Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 42 Ecuador GDP and Population, 2018-2019 ($)
Figure 43 Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 44 Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 45 Peru Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 46 Peru GDP and Population, 2018-2019 ($)
Figure 47 Peru GDP – Composition of 2018, By Sector of Origin
Figure 48 Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 49 Colombia Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 50 Colombia GDP and Population, 2018-2019 ($)
Figure 51 Colombia GDP – Composition of 2018, By Sector of Origin
Figure 52 Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 53 Costa Rica Amyotrophic Lateral Sclerosis MarketCosta Rica 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 54 Costa Rica GDP and Population, 2018-2019 ($)
Figure 55 Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 56 Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 57 Europe Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 58 U.K Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 59 U.K GDP and Population, 2018-2019 ($)
Figure 60 U.K GDP – Composition of 2018, By Sector of Origin
Figure 61 U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 62 Germany Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 63 Germany GDP and Population, 2018-2019 ($)
Figure 64 Germany GDP – Composition of 2018, By Sector of Origin
Figure 65 Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 66 Italy Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 67 Italy GDP and Population, 2018-2019 ($)
Figure 68 Italy GDP – Composition of 2018, By Sector of Origin
Figure 69 Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 70 France Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 71 France GDP and Population, 2018-2019 ($)
Figure 72 France GDP – Composition of 2018, By Sector of Origin
Figure 73 France Export and Import Value & Volume, 2018-2019 ($)
Figure 74 Netherlands Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 75 Netherlands GDP and Population, 2018-2019 ($)
Figure 76 Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 77 Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 78 Belgium Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 79 Belgium GDP and Population, 2018-2019 ($)
Figure 80 Belgium GDP – Composition of 2018, By Sector of Origin
Figure 81 Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 82 Spain Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 83 Spain GDP and Population, 2018-2019 ($)
Figure 84 Spain GDP – Composition of 2018, By Sector of Origin
Figure 85 Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 86 Denmark Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 87 Denmark GDP and Population, 2018-2019 ($)
Figure 88 Denmark GDP – Composition of 2018, By Sector of Origin
Figure 89 Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 90 APAC Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 91 China Amyotrophic Lateral Sclerosis MarketValue & Volume, 2021-2026
Figure 92 China GDP and Population, 2018-2019 ($)
Figure 93 China GDP – Composition of 2018, By Sector of Origin
Figure 94 China Export and Import Value & Volume, 2018-2019 ($)Amyotrophic Lateral Sclerosis MarketChina Export and Import Value & Volume, 2018-2019 ($)
Figure 95 Australia Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 96 Australia GDP and Population, 2018-2019 ($)
Figure 97 Australia GDP – Composition of 2018, By Sector of Origin
Figure 98 Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 99 South Korea Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 100 South Korea GDP and Population, 2018-2019 ($)
Figure 101 South Korea GDP – Composition of 2018, By Sector of Origin
Figure 102 South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 103 India Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 104 India GDP and Population, 2018-2019 ($)
Figure 105 India GDP – Composition of 2018, By Sector of Origin
Figure 106 India Export and Import Value & Volume, 2018-2019 ($)
Figure 107 Taiwan Amyotrophic Lateral Sclerosis MarketTaiwan 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 108 Taiwan GDP and Population, 2018-2019 ($)
Figure 109 Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 110 Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 111 Malaysia Amyotrophic Lateral Sclerosis MarketMalaysia 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 112 Malaysia GDP and Population, 2018-2019 ($)
Figure 113 Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 114 Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 115 Hong Kong Amyotrophic Lateral Sclerosis MarketHong Kong 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 116 Hong Kong GDP and Population, 2018-2019 ($)
Figure 117 Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 118 Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 119 Middle East & Africa Amyotrophic Lateral Sclerosis MarketMiddle East & Africa 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 120 Russia Amyotrophic Lateral Sclerosis MarketRussia 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 121 Russia GDP and Population, 2018-2019 ($)
Figure 122 Russia GDP – Composition of 2018, By Sector of Origin
Figure 123 Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 124 Israel Amyotrophic Lateral Sclerosis Market Value & Volume, 2021-2026 ($)
Figure 125 Israel GDP and Population, 2018-2019 ($)
Figure 126 Israel GDP – Composition of 2018, By Sector of Origin
Figure 127 Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 128 Entropy Share, By Strategies, 2018-2019* (%)Amyotrophic Lateral Sclerosis Market
Figure 129 Developments, 2018-2019*Amyotrophic Lateral Sclerosis Market
Figure 130 Company 1 Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 131 Company 1 Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 132 Company 1 Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 133 Company 2 Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 134 Company 2 Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 135 Company 2 Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 136 Company 3Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 137 Company 3Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 138 Company 3Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 139 Company 4 Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 140 Company 4 Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 141 Company 4 Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 142 Company 5 Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 143 Company 5 Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 144 Company 5 Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 145 Company 6 Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 146 Company 6 Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 147 Company 6 Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 148 Company 7 Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 149 Company 7 Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 150 Company 7 Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 151 Company 8 Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 152 Company 8 Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 153 Company 8 Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 154 Company 9 Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 155 Company 9 Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 156 Company 9 Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 157 Company 10 Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 158 Company 10 Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 159 Company 10 Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 160 Company 11 Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 161 Company 11 Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 162 Company 11 Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 163 Company 12 Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 164 Company 12 Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 165 Company 12 Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 166 Company 13Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 167 Company 13Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 168 Company 13Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 169 Company 14 Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 170 Company 14 Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 171 Company 14 Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)
Figure 172 Company 15 Amyotrophic Lateral Sclerosis Market Net Revenue, By Years, 2018-2019* ($)
Figure 173 Company 15 Amyotrophic Lateral Sclerosis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 174 Company 15 Amyotrophic Lateral Sclerosis Market Net Sales Share, By Geography, 2018 (%)